BioNxt Solutions Prepares for Human Bioequivalence Study For MS
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea
Picktan Capital Eyes a Public Listing on the LSE22.4.2025 09:10:00 CEST | Press release
Picktan Capital Explores Strategic Move Toward Public Listing on the London Stock Exchange in 2026. LONDON, UK / ACCESS Newswire / April 22, 2025 / Picktan Capital, the London-headquartered wealth management firm managing over $7 billion in client assets globally, has confirmed it is in active discussions with several major London-based investment banks to explore the possibility of a public listing on the London Stock Exchange (LSE) in 2026. The firm, known for its disciplined investment approach and bespoke wealth solutions, has formally notified its board of directors and shareholders of its intent to pursue a potential IPO. A strategic review process is currently underway to evaluate the most effective path to the public markets. At a recent shareholder meeting, the proposal to move forward with the listing received unanimous approval, highlighting widespread confidence in the company's direction, leadership, and future growth prospects. Founded with a mission to provide tailored,
ToolsGroup Recognized in the 2025 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions for the Second Consecutive Year22.4.2025 09:00:00 CEST | Press release
As a trusted partner to retailers, distributors, and manufacturers, ToolsGroup drives results in an uncertain world BOSTON, MA / ACCESS Newswire / April 22, 2025 / ToolsGroup, a global leader in supply chain planning and optimization software, is proud to announce that it has been included in the 2025 Gartner Magic Quadrant for Supply Chain Planning Solutions for the second consecutive year. For retailers, distributors, and manufacturers struggling to deliver results amidst uncertainty, ToolsGroup provides a breakthrough approach to supply chain planning that combines statistical modelling, advanced mathematical optimization, and AI. Customers have the power to shape demand and synchronize supply - replacing guesswork with precision. Built on decades of expertise and a unique probabilistic approach, ToolsGroup's Supply Chain Planning capabilities cover everything from S&OP and demand planning to inventory optimization, replenishment, and transport analytics. Powered by AI and real-time
IXOPAY Appoints Rachel Mae as Vice President of Sales to Execute Global Revenue Strategy Amid Accelerating Market Demand22.4.2025 06:00:00 CEST | Press release
Veteran sales leader joins IXOPAY to deepen customer engagement, expand international growth, and drive high-performance revenue strategy. LEHI, UT / ACCESS Newswire / April 22, 2025 / IXOPAY, a leading enterprise payment orchestration platform, today announced the appointment of Rachel Mae as Vice President of Sales. With over 20 years of experience building and leading high-performing sales organizations in software as a service (SaaS), financial technology (FinTech), and payments, Mae joins IXOPAY to scale the company's global revenue operations and expand its enterprise market footprint. Mae brings a proven track record of driving transformational sales strategies, enabling scalable growth, and developing customer-centric go-to-market teams. Her leadership will be instrumental as IXOPAY continues its global expansion and strengthens its position as the trusted partner for enterprises seeking resilience, flexibility, and optimization in their payment ecosystems. "Rachel brings the k
Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms21.4.2025 07:00:00 CEST | Press release
LUXEMBOURG, LU / ACCESS Newswire / April 21, 2025 / Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom